Shanghai Bao Pharmaceuticals Co (HKSE:02659) Total Equity: HK$1,758.69 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02659 Shanghai Bao Pharmaceuticals Co Ltd HKSE:02659
9 GF Score
Price HK$15.94
! 2 Warning Signs
View Full Analysis

What is Shanghai Bao Pharmaceuticals Co Total Equity?

Shanghai Bao Pharmaceuticals Co HKSE:02659 +0.25% 9 Total Equity is HK$1,758.69 Mil as of Dec. 2025. GuruFocus rates HKSE:02659 with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Shanghai Bao Pharmaceuticals Co's total equity for the quarter that ended in Dec. 2025 was HK$1,758.69 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Shanghai Bao Pharmaceuticals Co Total Equity Historical Data

* Premium members only.

The historical data trend for Shanghai Bao Pharmaceuticals Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shanghai Bao Pharmaceuticals Co Total Equity Chart

Shanghai Bao Pharmaceuticals Co Annual Data
Trend Dec23 Dec24 Dec25
Total Equity
819.38 1,063.27 1,758.69

Shanghai Bao Pharmaceuticals Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Total Equity 819.38 0.00 1,063.27 972.37 1,758.69
HKSE:02659
9GF Score
Shanghai Bao Pharmaceuticals Co Ltd HKSE:02659
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Shanghai Bao Pharmaceuticals Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Shanghai Bao Pharmaceuticals Co's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2449.152-690.459
=1,758.69

Shanghai Bao Pharmaceuticals Co's Total Equity for the quarter that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=2449.152-690.459
=1,758.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of HK$1,758.69 Mil mean?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a Total Equity of HK$1,758.69 Mil as of Dec. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Shanghai Bao Pharmaceuticals Co and its competitors.
Is Shanghai Bao Pharmaceuticals Co's Total Equity too high?
Shanghai Bao Pharmaceuticals Co's current Total Equity is HK$1,758.69 Mil. Overall, Shanghai Bao Pharmaceuticals Co has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Shanghai Bao Pharmaceuticals Co's Total Equity compare to VRTX and REGN?
Shanghai Bao Pharmaceuticals Co's Total Equity of HK$1,758.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Shanghai Bao Pharmaceuticals Co and its competitors. Shanghai Bao Pharmaceuticals Co's current Total Equity is HK$1,758.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Bao Pharmaceuticals Co stock overvalued right now?
Shanghai Bao Pharmaceuticals Co (HKSE:02659) has a current Total Equity of HK$1,758.69 Mil. The current Total Equity is HK$1,758.69 Mil. Shanghai Bao Pharmaceuticals Co's overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Shanghai Bao Pharmaceuticals Co (HKSE:02659), the current Total Equity is HK$1,758.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shanghai Bao Pharmaceuticals Co Business Description

Address No. 28 Luoxin Road, Baoshan District, Shanghai, CHN
Shanghai Bao Pharmaceuticals Co Ltd is a biotechnology company with an approved product and a diverse clinical pipeline, leveraging synthetic biology technology to develop and deliver recombinant biologic drugs in China, targeting conditions with limited treatment options and complex manufacturing challenges. The company has proprietary technology platforms, supported by its chassis cell engineering technology, that combine drug design and bioprocessing capabilities. It has production lines for finished dosage forms, including injectable solutions, lyophilized powder injections, and pre-filled syringes. The group has only one reportable operating segment, which is the research, development, and commercialisation of pharmaceutical products.
9GF Score

Get the complete analysis for HKSE:02659

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$15.94
Price